Dissecting Semax’s central melanocortin receptor MC4R binding mechanisms and its downstream neurotrophic effects via the BDNF-TrkB transcription pathway.

An exploration of the ACTH(4-10) analog Semax, focusing on TrkB receptor phosphorylation kinetics and transcriptomic upregulation of BDNF.

Preclinical analysis of Semax modulation of hippocampal BDNF/TrkB axis and downstream neuroprotection pathways.

A mechanistic review of how Semax engages melanocortin receptor pathways to drive CREB-dependent BDNF transcription, TrkB phosphorylation, and downstream MAPK/ERK and PI3K/Akt signaling in rodent hippocampal models.

A detailed scientific overview of the preclinical literature regarding Semax mechanisms.

This article explores the preclinical effects of Semax on suppressing inflammatory transcriptomic shifts and cytokine expression in cerebral ischemia models.

A preclinical research summary of Semax-associated transcriptomic changes in rat MCAO models, including BDNF/NGF/TrkB upregulation and inflammatory gene suppression in ischemic cortex.

This article examines Semax effects on striatal dopaminergic signaling in rodent models, covering DAT expression, D1/D2 receptor modulation, DOPAC/DA ratio changes, and the relationship with established BDNF/TrkB neurotrophic pathways.

Preclinical analysis of Semax heptapeptide neurotrophic pathways, transcriptional BDNF/NGF upregulation, and melanocortin receptor interactions.

An analysis of Semax’s reported effects on BDNF and NGF expression, TrkB receptor phosphorylation, monoaminergic system modulation, and melanocortin receptor interactions in preclinical brain injury and ischemia research models.